B. Kam

发表

Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours

E. Krenning, W. D. de Herder, W. A. van der Zwan, 2018, European Journal of Nuclear Medicine and Molecular Imaging.

Peptide-receptor radionuclide therapy for endocrine tumors

R. Valkema, E. Krenning, M. Jong, 2009, Nature Reviews Endocrinology.

Preclinical and clinical studies of peptide receptor radionuclide therapy.

R. Valkema, E. Krenning, C. V. van Eijck, 2010, Seminars in nuclear medicine.

Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course

E. Krenning, C. V. van Eijck, D. Kwekkeboom, 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[(111)In-DTPA]octreotide tumor uptake in GEPNET liver metastases after intra-arterial administration: an overview of preclinical and clinical observations and implications for tumor radiation dose after peptide radionuclide therapy.

E. Krenning, C. V. van Eijck, G. Koning, 2014, Cancer biotherapy & radiopharmaceuticals.

Lutetium-labelled peptides for therapy of neuroendocrine tumours

E. Krenning, D. Kwekkeboom, W. D. de Herder, 2012, European Journal of Nuclear Medicine and Molecular Imaging.

Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.

E. Krenning, C. V. van Eijck, D. Kwekkeboom, 2010, Seminars in nuclear medicine.

Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.

R. Valkema, E. Krenning, M. Jong, 2010, Endocrine-related cancer.

Tumor Response Assessment to Treatment with [177Lu-DOTA0,Tyr3]Octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors: Differential Response of Bone Versus Soft-Tissue Lesions

E. Krenning, R. D. de Krijger, J. Hermans, 2012, The Journal of Nuclear Medicine.

Gastroenteropancreatic and Bronchial Neuroendocrine Tumors: Differential Response of Bone Versus Soft-Tissue Lesions

Erasmus Mc, E. Krenning, J. Hermans, 2012 .

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors.

E. Krenning, C. V. van Eijck, D. Kwekkeboom, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Feasibility and image quality of dual-isotope SPECT using 18F-FDG and (99m)Tc-tetrofosmin after acipimox administration.

Jeroen J. Bax, J. Roelandt, R. Valkema, 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate

E. Krenning, C. V. van Eijck, B. Bonsing, 2015, The Journal of Nuclear Medicine.

Treatment of Gastroenteropancreatic Neuroendocrine Tumors with Peptide Receptor Radionuclide Therapy

E. Krenning, M. de Jong, D. Kwekkeboom, 2012, Neuroendocrinology.

Peptide receptor radionuclide therapy (PRRT) for GEP-NETs.

E. Krenning, R. Peeters, D. Kwekkeboom, 2012, Best practice & research. Clinical gastroenterology.

Salvage therapy with 177Lu-octreotate in patients with gastroenteropancreatic neuroendocrine tumors

E. Krenning, M. Essen, D. Kwekkeboom, 2009 .

Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues.

R. Valkema, E. Krenning, D. Kwekkeboom, 2007, Hematology/oncology clinics of North America.

Salvage Therapy with 177Lu-Octreotate in Patients with Bronchial and Gastroenteropancreatic Neuroendocrine Tumors

E. Krenning, D. Kwekkeboom, W. D. de Herder, 2010, Journal of Nuclear Medicine.

Quality of Life in 265 Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors Treated with [177Lu-DOTA0,Tyr3]Octreotate

E. Krenning, D. Kwekkeboom, B. Kam, 2011, The Journal of Nuclear Medicine.

Somatostatin Analogues and Radionuclides Used in Therapy

E. Krenning, M. Jong, D. Kwekkeboom, 2015 .

Peptide Receptor Radionuclide Therapy in Patients with Somatostatin Receptor‐Positive Neuroendocrine Tumors

R. Valkema, E. Krenning, M. Jong, 2010 .

Endocrine Gastroenteropancreatic Tumors

E. Krenning, D. Kwekkeboom, B. Kam, 2005 .

Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate

E. Krenning, B. de Keizer, D. Kwekkeboom, 2008, European Journal of Nuclear Medicine and Molecular Imaging.

et al Treatment with the radiolabeled somatostatinanalog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival Journal of Clinical Oncology :

M. Essen, D. Kwekkeboom, B. Kam, 2008 .

E. Krenning, D. Kwekkeboom, K. Lom, 2017 .

Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours

E. Krenning, D. Kwekkeboom, W. D. de Herder, 2008, European Journal of Nuclear Medicine and Molecular Imaging.

Comparison of Response Evaluation in Patients with Gastroenteropancreatic and Thoracic Neuroendocrine Tumors After Treatment with [177Lu-DOTA0,Tyr3]Octreotate

E. Krenning, D. Kwekkeboom, B. Kam, 2013, The Journal of Nuclear Medicine.

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.

E. Krenning, C. V. van Eijck, D. Kwekkeboom, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate

E. P. Krenning, W. H. Bakker, E. Krenning, 2003, European Journal of Nuclear Medicine and Molecular Imaging.

Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.

Marion de Jong, R. Valkema, E. Krenning, 2010, Endocrine-related cancer.

Predictive Value of CYP3A and ABCB1 Phenotyping Probes for the Pharmacokinetics of Sunitinib: the ClearSun Study

A. Zwinderman, Y. Daali, J. Schellens, 2014, Clinical Pharmacokinetics.

Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience.

R. Valkema, E. Krenning, M. Stridsberg, 2002, Seminars in nuclear medicine.

Inhibition of kidney uptake of radiolabeled somatostatin analogs: amino acids or gelofusine?

R. Valkema, E. Rolleman, E. Krenning, 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Hypocalcaemia after treatment with [177Lu-DOTA0,Tyr3]octreotate

E. Krenning, R. Peeters, D. Kwekkeboom, 2013, European Journal of Nuclear Medicine and Molecular Imaging.

The use of both diagnostic and therapeutic MIBG in neuroblastoma patients

B. Hero, R. Versteeg, H. Caron, 2014 .

Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE.

R. M. Metselaar, E. Korpershoek, R. Oldenburg, 2019, European journal of endocrinology.

Salvage Therapy with 177Lu-Octreotate in Patients with Bronchial and Gastroenteropancreatic Neuroendocrine Tumors

E. Krenning, D. Kwekkeboom, W. D. de Herder, 2010, Journal of Nuclear Medicine.

Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate

E. Krenning, C. V. van Eijck, B. Bonsing, 2015, The Journal of Nuclear Medicine.